You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
資金動向 | 北水小幅加倉港股,連續買入小米、康方生物

8月11日,南下資金淨買入港股3834.39萬港元。

其中,淨買入小米集團-W 5.62億、康方生物3.05億、東方甄選1.87億、晶泰控股1.16億;

淨賣出小鵬汽車-W 6.64億、信達生物5.27億、騰訊控股3.39億、美團-W 2.64億、阿里巴巴-W 2.33億、中芯國際2.37億。

據統計,南下資金已連續3日淨買入小米,共計27.5701億港元;連續5日淨買入康方生物、共計11.8185億港元。

北水關注個股

小米集團今日微跌0.88%,連續5個交易日收綠。中金髮表報告,預計小米集團第二季度收入將達1179.7億元,按年增長32.71%,經調整淨利潤101.8億元,按年增長64.84%(包含電動車及創新業務3.6億元虧損)。該行將小米目標價下調9%至70港元,對應2025及2026年市盈率分別爲34.4倍和25.1倍,潛在上行空間29.6%,維持“跑贏行業”評級。

小鵬汽車今日大漲5.36%。小鵬汽車首款增程車型——小鵬X9增程版MPV已於8月8日進入工信部新一批新車公示清單,這意味着該車距離上市愈來愈近。小鵬汽車CEO何小鵬、發文表示,首款“超級電動車型”小鵬X9將會在第四季度正式推出。

信達生物今日跌1.42%。中信證券認爲,2025年下半年醫療健康產業的業績和估值修復趨勢確定性較高,同時分化也將更加明顯,擁抱創新驅動和國際化+自主可控+院外營銷模式改革將是相對更有確定性的佈局方向。考慮到創新藥板塊除海外斬獲外,新增國內政策大力支持,醫藥真創新和真國際化時代將迎來回報,有望帶動板塊穩步向上。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account